Net profit of Sandu Pharmaceuticals declined 9.09% to Rs 0.50 crore in the quarter ended September 2024 as against Rs 0.55 crore during the previous quarter ended September 2023. Sales rose 6.56% to Rs 17.70 crore in the quarter ended September 2024 as against Rs 16.61 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales17.7016.61 7 OPM %5.144.94 - PBDT0.910.90 1 PBT0.740.76 -3 NP0.500.55 -9 Powered by Capital Market - Live News

Net profit of Sandu Pharmaceuticals declined 9.09% to Rs 0.50 crore in the quarter ended September 2024 as against Rs 0.55 crore during the previous quarter ended September 2023. Sales rose 6.56% to Rs 17.70 crore in the quarter ended September 2024 as against Rs 16.61 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales17.7016.61 7 OPM %5.144.88 - PBDT0.910.89 2 PBT0.740.76 -3 NP0.500.55 -9 Powered by Capital Market - Live News

Sandu Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live News

Sandu Pharmaceuticals announced that the 39th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live News

Sandu Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 12 August 2024, inter alia, have recommended the final dividend of Rs 0.8 per equity Share (i.e. 8%) , subject to the approval of the shareholders.Powered by Capital Market - Live News